Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | EBP | Q15125 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.41 |
| ▸ | GUSB | P08236 | 2/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20858268 | 1.00 | SIGMAR1 (0.44) | SIGMAR1EBPGNAI3GNAO1GNAI1 | |
| SCHEMBL26718337 | 0.92 | GLB1 (0.36) | SIGMAR1EBPGNAI3GNAO1GNAI1 | |
| SCHEMBL12674082 | 0.83 | L3MBTL3 (0.34) | — | |
| SCHEMBL22859605 | 0.81 | S1PR1 (0.49) | SIGMAR1EBPGNAI3GNAO1GNAI1 | |
| SCHEMBL25653853 | 0.81 | S1PR1 (0.44) | SIGMAR1EBPGNAI3GNAO1GNAI1 | |
| SCHEMBL25834628 | 0.79 | GNAI3 (0.44) | SIGMAR1EBPGNAI3GNAO1GNAI1 | |
| SCHEMBL23480987 | 0.78 | DNM1 (0.33) | SIGMAR1EBP | |
| SCHEMBL26580522 | 0.77 | EGFR (0.31) | — | |
| SCHEMBL26894648 | 0.76 | GNAO1 (0.43) | SIGMAR1EBPGNAI3GNAO1GNAI1 | |
| SCHEMBL23554783 | 0.76 | S1PR1 (0.43) | SIGMAR1EBPGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-10253018-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253018-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, CASP1, BAX | SIGMAR1 2083/4885EBP 668/4885GNAI3 1630/4885 |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SIGMAR1 3199/4885EBP 3184/4885GNAI3 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.